I have been actively involved for more than two decades in developing and implementing new imaging methods for examination of disease processes, with a focus on translatable technology and early therapeutic response assessment. I am interested in the early phases of translation of new radiopharmaceuticals or novel applications of approved agents to develop and improve such readouts. I have a long standing interest in the tumor microenvironment, cell surface receptors, and metabolic alterations; imaging processes in cardiovascular disease; and imaging targets in autoimmune disease, evaluated using PET, SPECT, optical, and MR methods.